On August 24, 2026, the United States District Court for the Southern District of California granted preliminary approval of a settlement resolving the derivative action, under which defendants have agreed to implement various corporate reforms.

In a status report filed on May 19, 2026, the parties to a shareholder derivative action brought on behalf of Acadia Pharmaceuticals in California federal court advised that they had substantially completed documenting a settlement of the claims asserted therein and in certain related stockholder demands, including a stockholder demand served by KSF.